NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-08-07 18:50இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Albert David Approves ₹5.00 Dividend and Appoints New CEO for 5-Year Term
Albert David Limited's shareholders approved all seven resolutions at the 87th AGM held on August 6, 2026. Key outcomes include the declaration of a ₹5.00 per share dividend for FY26 and the formal appointment of Mr. Amit Mahla as CEO and Whole-time Director for a five-year term. The company also ratified a revision in remuneration for the Executive Chairman, Mr. Arun Kumar Kothari, for FY27. Voting participation was consistent, with approximately 64.61% of the total 57.07 lakh issued shares represented in the poll.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned to a new CEO, Mr. Amit Mahla, and formalized its dividend payout and executive compensation structure for the upcoming fiscal year.
ஏன் இது முக்கியம்The formalization of a 5-year CEO term provides leadership stability, while the dividend maintains shareholder returns despite the company's low ROCE and product concentration risks in placenta-based drugs.
📅 குறுகிய காலம்Neutral; the stock may see minor activity around the dividend payout, but the AGM results were largely procedural and expected.
📈 நீண்ட காலம்The long-term outlook depends on the new CEO's ability to diversify the product pipeline beyond placenta-based drugs and improve manufacturing efficiency through the planned technology upgrades.
⚠ அபாய எச்சரிக்கைகள்
Low ROCE of 1.0%
High product concentration in placenta-based drugs
Regulatory risks associated with pharmaceutical manufacturing standards
👀 கவனிக்க வேண்டியவை
Investors should monitor the strategic direction under the new CEO, Mr. Amit Mahla, particularly regarding the company's stated goal of upgrading facilities to Revised Schedule-M standards and improving the current 1.0% ROCE.
₹5 Dividend and CEO Appointment Confirmed at Albert David's 87th AGM
Albert David Limited concluded its 87th Annual General Meeting on August 6, 2026, where shareholders approved a dividend of ₹5 per equity share for FY26. A significant leadership transition was formalized with the appointment of Mr. Amit Mahla as Whole-time Director & CEO for a five-year term ending June 2031. Additionally, shareholders voted on the revision of remuneration for Executive Chairman Mr. Arun Kumar Kothari and the ratification of cost auditors for FY27. The meeting also adopted the audited financial statements for the year ended March 31, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its top leadership structure for the next five years and confirmed the dividend payout for the previous fiscal year.
ஏன் இது முக்கியம்Leadership continuity under a new CEO is critical as the company navigates facility upgrades and R&D for new molecules. The dividend provides a tangible return to shareholders from the FY26 earnings.
Dividend per share: ₹5CEO Appointment Term: 5 yearsCut-off Date: ஜூலை 30, 2026Face Value: ₹10கடன்: ₹30 கோடி
📅 குறுகிய காலம்The stock price may reflect the dividend confirmation in the coming weeks as the payout process initiates.
📈 நீண்ட காலம்The five-year CEO mandate provides structural stability for the company's long-term goal of penetrating new markets and strengthening its product pipeline.
Product concentration risk in placenta-based drugs
👀 கவனிக்க வேண்டியவை
Investors should monitor the final voting results for any significant dissent regarding executive remuneration revisions. The focus should remain on the new CEO's ability to execute the company's strategy of upgrading facilities to Revised Schedule-M standards.
Resignation of Head of R&D Dr. Kuntal Ganguly Effective August 5, 2026
Albert David Limited has announced the resignation of Dr. Kuntal Ganguly, the Head of Research & Development (R&D), effective from the close of business on August 5, 2026. The resignation is attributed to personal reasons. This departure is notable as the company's qualitative strategy emphasizes R&D focus on new molecules and drug delivery systems to drive future growth. No immediate successor has been named in the filing.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe leadership of the Research & Development department has become vacant following the resignation of Dr. Kuntal Ganguly.
ஏன் இது முக்கியம்For a pharmaceutical company focused on upgrading manufacturing standards and developing new drug delivery systems, the Head of R&D is a critical role for maintaining the product pipeline and long-term competitiveness.
Effective Date of Cessation: ஆகஸ்ட் 5, 2026Net Worth: Rs 392 கோடிகடன்: Rs 30 கோடிPromoter Holding: 62.24%
📅 குறுகிய காலம்The stock may see neutral to cautious sentiment as the market evaluates the impact of leadership turnover in a core technical function.
📈 நீண்ட காலம்The long-term impact depends on the company's ability to recruit a qualified successor to lead its R&D-driven growth and diversification strategy.
⚠ அபாய எச்சரிக்கைகள்
Key person dependency in R&D
Potential delay in new product pipeline development
👀 கவனிக்க வேண்டியவை
Investors should watch for the appointment of a new R&D head and any updates regarding the timeline for new molecule development or facility upgrades to Revised Schedule-M standards.
Albert David Submits Q1 FY2026-27 Results; Board Meeting Concluded on Aug 6
Albert David Limited has released its unaudited financial results for the quarter ended June 30, 2026. The board meeting, held on August 6, 2026, lasted approximately 3 hours and 40 minutes. The company maintains a conservative capital structure with a debt of Rs 30 Cr against a net worth of Rs 392 Cr (D/E ratio of 0.08). Investors should monitor the detailed P&L for improvements in ROCE, which was recently reported at a low 1.0%.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுThe company has formally reported its financial performance for the first quarter of the 2026-27 fiscal year, following board approval.
ஏன் இது முக்கியம்This is a routine but essential disclosure that provides transparency into the company's current financial health and its progress on upgrading manufacturing units for cost control.
📅 குறுகிய காலம்The stock may see neutral to range-bound movement as the market digests the specific revenue and profit figures from the detailed filing.
📈 நீண்ட காலம்Long-term value depends on the company's ability to diversify its product pipeline and improve its low ROCE through better manufacturing efficiency and market expansion.
⚠ அபாய எச்சரிக்கைகள்
Product concentration risk (placenta-based drugs)
Low ROCE of 1.0%
Regulatory risks inherent to pharmaceutical manufacturing
👀 கவனிக்க வேண்டியவை
Review the full financial tables for revenue growth and operating margins to see if R&D investments in new molecules are offsetting product concentration risks in placenta-based drugs.
Albert David Credit Ratings Reaffirmed at 'CARE A'; Outlook Remains Negative
CARE EDGE Ratings has reaffirmed Albert David Limited's long-term rating at 'CARE A' and short-term rating at 'CARE A1'. The outlook for the long-term facilities remains 'Negative', indicating potential risks to the company's credit profile or financial performance. The total rated bank facilities have been slightly reduced to ₹62.50 crore from the previous ₹64.50 crore. This review follows the assessment of the company's financial performance for the fiscal year 2026.
முக்கிய அம்சங்கள்
Long-term bank facilities of ₹50.50 crore reaffirmed at 'CARE A' with a 'Negative' outlook.Short-term bank facilities of ₹12.00 crore reaffirmed at 'CARE A1'.Total rated bank facilities decreased by ₹2.00 crore, from ₹64.50 crore to ₹62.50 crore.Rating review was based on the company's operational and financial performance for FY26.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming financial results to see if operational performance improves enough to stabilize the 'Negative' outlook. While the reaffirmation shows current stability, the outlook suggests a need for caution regarding future credit health.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Albert David Appoints Amit Mahla as Whole-time Director & CEO for 5-Year Term
Albert David Limited has officially appointed Mr. Amit Mahla as an Additional Director and Whole-time Director & CEO for a five-year tenure effective June 19, 2026. Mr. Mahla, who has served as the company's CEO since May 12, 2026, brings over 28 years of experience from major pharmaceutical firms including Cipla, Sun Pharma, and JB Pharma. The appointment and his remuneration for the period ending March 31, 2027, are subject to shareholder approval at the upcoming 87th Annual General Meeting. This move is aimed at leveraging his expertise in business transformation and strategic leadership within the Indian Pharmaceutical Market.
முக்கிய அம்சங்கள்
Appointment of Mr. Amit Mahla as Whole-time Director & CEO for a 5-year term from June 19, 2026, to June 18, 2031.Mr. Mahla possesses over 28 years of industry experience with leadership roles at Cipla, Sun Pharma, and JB Pharma.The Board has revised the 87th AGM notice to include shareholder approval for this appointment and remuneration fixation.The appointee previously led the integration of Sanzyme into JB Pharma, demonstrating high-level M&A and integration expertise.Remuneration for the initial period from June 19, 2026, to March 31, 2027, has been approved by the Board.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming 87th AGM for shareholder approval of the appointment, as Mr. Mahla's extensive background in top-tier pharma companies could signal a strategic growth phase for the company.
Albert David Reports Q4 Net Loss of ₹21.43 Cr Impacted by Negative Other Income
Albert David Limited reported a significant net loss of ₹21.43 crore for the quarter ended March 31, 2026, primarily driven by an unusual negative 'Other Income' figure of ₹24.84 crore. For the full financial year 2025-26, the company posted a consolidated net loss of ₹1.49 crore on a total revenue from operations of ₹333.60 crore. Despite the bottom-line pressure, the company maintains a robust liquidity position with current investments valued at ₹225.05 crore. The quarterly EPS stood at a negative ₹37.56, reflecting the sharp downturn in profitability during the final period.
முக்கிய அம்சங்கள்
Q4 FY26 revenue from operations was ₹85.86 crore, but total income dropped to ₹61.03 crore due to negative other income.Net loss for Q4 FY26 stood at ₹21.43 crore, leading to a full-year net loss of ₹1.49 crore.Total expenses for the full year FY26 were ₹340.53 crore against a total income of ₹341.05 crore.Strong balance sheet maintained with total equity of ₹391.54 crore and current investments of ₹225.05 crore.Basic and Diluted EPS for the full year FY26 ended at negative ₹2.62.
👀 கவனிக்க வேண்டியவை
Investors should seek clarification regarding the significant negative 'Other Income' of ₹24.84 crore in Q4, which appears to be a non-operational write-down or adjustment. While the core pharmaceutical operations remain steady, the sudden quarterly loss warrants a cautious approach until the nature of the income adjustment is understood.
Albert David Appoints Amit Mahla as CEO; Recommends Rs 5.00 Final Dividend
Albert David Limited has appointed Mr. Amit Mahla as the new CEO, bringing over 28 years of experience from top pharma firms like Sun Pharma and JB Pharma. The Board recommended a final dividend of Rs. 5.00 per share (50% of face value) for FY 2025-26, with a record date set for July 30, 2026. The company reported audited financial results for the year ended March 31, 2026, with an unmodified audit opinion from M/s. L. B. Jha & Co. Additionally, PwC Services LLP has been re-appointed as internal auditors for the upcoming fiscal year.
முக்கிய அம்சங்கள்
Appointment of Mr. Amit Mahla as CEO effective May 12, 2026, bringing 28+ years of pharma experience from Cipla, Sun Pharma, and JB Pharma.Recommended a final dividend of Rs. 5.00 per equity share (50% of face value) for the financial year ended March 31, 2026.Record date for dividend and AGM voting eligibility fixed as July 30, 2026, with the AGM scheduled for August 6, 2026.Re-appointment of Big 4 firm PwC Services LLP as Internal Auditors for the financial year 2026-27.Audited financial results for FY 2025-26 approved with an unmodified audit opinion from statutory auditors.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's growth trajectory and potential business transformation under the new CEO's leadership. The Rs. 5.00 dividend provides a steady yield for shareholders ahead of the record date on July 30.
Albert David Appoints New CEO, Recommends Rs 5 Dividend; Record Date July 30
Albert David Limited has appointed Mr. Amit Mahla as the new CEO, bringing over 28 years of pharmaceutical experience from firms like JB Pharma and Sun Pharma. The board recommended a final dividend of Rs 5.00 per share (50% of face value) for FY 2025-26, with July 30, 2026, set as the record date. Financial results for the year ended March 31, 2026, were approved with an unmodified audit opinion. Additionally, the company re-appointed PwC as internal auditors for the upcoming fiscal year.
முக்கிய அம்சங்கள்
Appointment of Mr. Amit Mahla as CEO effective May 12, 2026, with 28+ years of pharma experience.Recommendation of a final dividend of Rs 5.00 per equity share (50% of face value) for FY26.Record date for dividend eligibility and 87th AGM voting fixed as July 30, 2026.Audited financial results for FY26 approved with an unmodified statutory audit report.Re-appointment of PwC Services LLP as internal auditors for FY 2026-27.
👀 கவனிக்க வேண்டியவை
Investors should ensure they hold shares before the July 30 record date to qualify for the Rs 5 dividend and track the impact of the new CEO's leadership on business growth.
Albert David Q3 Results: Net Profit at ₹15.30 Cr vs Loss of ₹9.39 Cr YoY; Revenue Up 8%
Albert David Limited reported a significant turnaround in Q3 FY26, posting a net profit of ₹15.30 crore compared to a net loss of ₹9.39 crore in the same period last year. Revenue from operations grew 8.2% YoY to ₹89.93 crore, while sequential growth was also positive. The bottom line was heavily supported by a sharp rise in 'Other Income' which reached ₹12.40 crore. However, on a nine-month basis, the net profit of ₹19.94 crore still lags behind the ₹27.53 crore recorded in the previous year.
முக்கிய அம்சங்கள்
Revenue from operations increased 8.2% YoY to ₹8,992.69 Lakhs from ₹8,308.29 Lakhs.Net Profit turned positive at ₹1,530.38 Lakhs against a loss of ₹938.78 Lakhs in Q3 FY25.Other Income spiked to ₹1,239.93 Lakhs compared to a negative ₹900.67 Lakhs in the year-ago period.Earnings Per Share (EPS) recovered to ₹26.81 from a negative ₹16.45 YoY.Total expenses for the quarter were lower at ₹8,242.37 Lakhs compared to ₹8,423.69 Lakhs YoY.
👀 கவனிக்க வேண்டியவை
Investors should view the return to profitability positively, but must scrutinize the high 'Other Income' component to determine if it is a one-time gain or sustainable. The stock remains a watch to see if operational revenue growth can continue to offset the nine-month performance lag.
Albert David MD & CEO Umesh Manohar Kunte Resigns Effective December 18, 2025
Albert David Limited has announced the resignation of Mr. Umesh Manohar Kunte from his positions as Managing Director, Chief Executive Officer, and Director. The resignation is effective from the close of business hours on December 18, 2025, citing personal reasons and priorities. Consequently, Mr. Kunte also ceases to be a Key Managerial Person (KMP) of the company. The Board of Directors accepted the resignation during a meeting that concluded at 19:20 HRS on the same day.
முக்கிய அம்சங்கள்
Mr. Umesh Manohar Kunte (DIN: 03398438) resigns as MD, CEO, and Director effective Dec 18, 2025.The resignation is attributed to personal reasons and priorities of the outgoing executive.Mr. Kunte will no longer serve as a Key Managerial Person (KMP) under Section 203 of the Companies Act.The Board meeting approving the transition took place on December 18, 2025, from 17:00 to 19:20 HRS.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's next steps regarding the appointment of a new CEO/MD to ensure leadership continuity. Any delay in finding a replacement or a shift in strategic direction should be watched closely.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
